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As neglected tropical disease programs look to consolidate the successes of moving towards elimination, we need to understand 
the dynamics of transmission at low prevalence to inform surveillance strategies for detecting elimination and resurgence. In this 
special collection, modelling insights are used to highlight drivers of local elimination, evaluate strategies for detecting resurgence, 
and show the importance of rational spatial sampling schemes for several neglected tropical diseases (specifically schistosomiasis, 
soil-transmitted helminths, lymphatic filariasis, trachoma, onchocerciasis, visceral leishmaniasis, and gambiense sleeping sickness).
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WHERE WE HAVE BEEN...
Mathematical modelling of neglected tropical diseases (NTDs) 
has strengthened and diversified over the past decade, in parallel 
with extraordinary achievements in scaling up NTD programs. 
The NTD Modelling Consortium, a research project funded by 
the Bill and Melinda Gates Foundation, was formed in 2014 to 
support the efforts around a small number of key diseases [1]. 
The consortium was formed of at least 2 international model-
ling groups working on each disease to provide robust scientific 
insight, based on the available data. One of the priority tasks was 
to evaluate strategies to achieve the World Health Organization 
2020 goals [2]. Whilst providing evidence-based modelling re-
commendations to inform policy makers, the process of model 
comparison is critical to the development of models, improving 
the robustness of results and thereby supporting policy makers 
to trust the models [3, 4]. However, this is not a static process 
as model developments and comparisons have continued to 
respond to an evolving evidence base [5]. The consortium 
has also identified data needs across surveillance programs to 
monitor progress and to address epidemiological uncertainties 
to strengthen the scientific evidence underlying the model as-
sumptions and inform programs more directly [6].
As NTD programs move towards achieving their goals and 
deciding whether they can stop treatment, there will be a crit-
ical shift towards potential elimination, with the accompanying 
demand for more robust surveillance in order to ensure that the 
hard-won gains are not lost. In this special collection, we inves-
tigate the dynamics of low-prevalence transmission for several 
NTDs, namely, schistosomiasis, soil-transmitted helminths, 
lymphatic filariasis, trachoma, onchocerciasis, visceral leish-
maniasis, and gambiense sleeping sickness. We provide guid-
ance on the surveillance that will be required once programs 
are halted.
ROLLING THE DICE: DYNAMICS OF ELIMINATION 
AND RESURGENCE
The NTDs are unusual in that interventions, particularly 
mass drug administration (MDA), are often halted, unlike 
vaccine-preventable diseases which typically have longer-
lasting programs. Once interventions reduce the prevalence of 
an infection to a low level, the final few cases may infect few 
or no other cases and the infection may be eliminated. There 
is stochasticity surrounding this process, with chance events 
leading to either elimination or resurgence (Figure 1). However, 
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there are conditions that can weigh the probability of elimina-
tion and drive it higher or lower.
It is important to remember that for many NTDs reinfection 
can occur, and this also means that in theory prevalence could 
return to preintervention levels once programs are halted. Slow 
epidemic growth rates for these infections means that there are 
opportunities to detect resurgence but, equally, as resurgence 
could take years to detect, the political will may have waned by 
the time they are detected, and screening programs will have to 
be in place throughout this time to detect these resurgent cases.
The most important driver of resurgence is the underlying 
transmission rate. For the NTDs addressed in this collection, 
the first line of attack is targeted at treatment of human cases, 
to reduce the burden of disease. However, as case numbers drop 
and elimination comes into prospect, transmission reduction 
through other interventions, such as vector control and sani-
tation, becomes crucial in reducing the probability and speed 
of resurgence, particularly when MDA or screening programs 
are halted. Surveillance activities for detecting elimination and 
resurgence become increasingly important to ensure that suc-
cesses are maintained.
BALANCING ACT: DESIGNING PRACTICAL 
SURVEILLANCE SCHEMES FOR ELIMINATION
When targeting elimination of NTDs across large areas, it is 
impossible to sample everyone or every community to con-
firm that the incidence of infection has been reduced to zero. 
Therefore any surveillance scheme is inherently associated with 
some degree of uncertainty. The greater the “effort” made in 
surveillance, the lower this uncertainty. Such surveillance means 
an increase in costs. However, once elimination is affirmed, the 
costs stop whilst the benefits continue to accumulate over time 
[8]. Hence, bigger efforts for detecting elimination may be more 
cost-effective, or even cost-saving, in the long term.
Given the difficulty in measuring zero incidence, practical 
thresholds can be determined and used in lieu of this. These 
thresholds are typically based on a prevalence of infection 
measure, whereby once this prevalence is reached, elimina-
tion or resurgence probabilities can be estimated. It is impor-
tant to remember that whatever the threshold, there is some 
probability that resurgence will happen, and postvalidation 
surveillance is essential. The level of accuracy required, or im-
posed by cost constraints, will affect the surveillance criteria, 
that is specifying a 90% certainty of elimination will mean we 
can have a higher threshold for stopping treatment relative to 
95% certainty. For schistosomiasis, by reaching 1% Kato-Katz 
prevalence 2 years after stopping MDA we can be 90% certain 
elimination will occur, whereas the certainty is 75% once 5% 
prevalence has been reached [7]. In addition to this threshold, 
surveillance schemes also need to provide guidance on when to 
sample, who to sample, and how to sample.
KEY CONSIDERATIONS
When to Sample
Most NTDs have slow epidemic growth rates and, therefore, if 
there is resurgence, it may take years to be detected. Likewise, 
elimination can take years to occur as low-prevalence settings 
may approach zero slowly. Surveillance to detect elimination or 
resurgence will usually need to be carried out more than once 
depending on the disease. For lymphatic filariasis, resurgence 
can occur outside of the currently recommended surveillance 
period of 4–6  years. Hence, post-MDA monitoring would be 
needed for longer to ensure success [9].
For diseases where case management is the main strategy, in-
tensified testing and case finding is important (Figure 2). The 
timing of stepping back active and passive case detection is key. 
Frequently, the treatment of cases is the principal intervention, 
that is surveillance and control are combined. Active surveil-
lance showing no detected cases over multiple years can provide 
more confidence of elimination, relative to a single year of ac-
tive surveillance as shown for gambiense sleeping sickness [11]. 
As cases fall, there are risks of declining quality of surveillance, 
including higher delays in case detection times and losses in 
skills of identifying cases. Hence, monitoring the performance 
of case detection programs is important and incidence alone 
may not be a sufficient measure. For visceral leishmaniasis, 
although relaxation of detection efforts may lead to an initial 
decline in observed incidence, this comes with a high risk of re-
surgence. Here, the duration of symptoms in detected cases can 
be informative in assessing the performance of case detection 
programs [10]. For such diseases, finding an alternative means 
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Figure 1. Elimination dynamics: simulations showing the stochasticity around 
achieving elimination or resurgence after stopping a mass treatment program (figure 
adapted from [7] for schistosomiasis; http://creativecommons.org/licenses/by/4.0/). 
At the posttreatment surveillance time point, if the prevalence threshold is reached, 
we can predict with a certain probability that elimination will occur (likewise, if we 
are above this threshold, we can predict that resurgence will occur). Multiple sur-
veillance time points will likely be required at a frequency depending on the disease 
because resurgence will always be a risk before diseases are eradicated.
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of assessing transmission is an invaluable surveillance activity 
to ensure elimination [12].
Who to Sample
The criteria of who to sample can vary from sampling a spe-
cific number of people from the whole population at random to 
sampling more purposively from a particular subgroup(s). This 
decision depends on the epidemiology of the disease, particu-
larly the age-dependent exposure rates. These rates can vary ge-
ographically across communities and countries. Data required 
to inform this (ie, infection data across all age groups) are lim-
ited for the NTDs. Hence, we have to use assumptions regarding 
epidemiology but these will affect the efficacy of the threshold. 
For onchocerciasis, assuming different exposure patterns re-
sults in either children younger than 10 years old or children 
5–14 years old being the most informative age groups for sero-
logical monitoring [5]. The analyses in this collection have been 
careful to examine the uncertainty surrounding these conclu-
sions and identify focused empirical studies that would inform 
these estimates and improve the robustness of such results.
Notably, the decision of who to sample also needs to be made 
at the early stages of a program as this plays a role in deter-
mining the optimal treatment strategy. For schistosomiasis, 
children and adults need to be sampled, particularly in high-
prevalence settings, in order to determine the coverage levels 
required within a program [13].
How to Sample
The question of how to sample revolves around the diag-
nostic technique that has been used to measure the threshold 
for detecting elimination. As diagnostic tests for NTDs differ 
in terms of their sensitivity and specificity, the diagnostic used 
will impact the surveillance criteria and the certainty of our 
measures. Better diagnostics will allow policy makers to make 
the most cost-effective decisions, particularly as they will im-
prove the detection of elimination and resurgence [14]. This 
is evident with trachoma, where an increase in trachomatous 
inflammation-follicular prevalence in children 1–9  years old 
may be a result of resurgence or measurement error [15].
The budget for surveillance will play a role given that the costs 
associated with each diagnostic approach will vary. Despite 
new techniques having potentially higher unit costs, this may 
be outweighed by the long-term programmatic benefits of 
being able to detect elimination [14]. For the NTDs such as 
the soil-transmitted helminths and schistosomiasis, given lim-
ited resources, multiple samples per individual means sampling 
fewer individuals. Using a set budget for the soil-transmitted 
helminths, a single-slide Kato-Katz technique would be suffi-
cient to evaluate both prevalence of any and moderate-to-heavy 
intensity of infection during the early program stages, whereas 
more sensitive sampling schemes may be required for decisions 
involving stopping MDA [16].
Spatial Heterogeneity
When designing surveillance schemes, spatial heterogeneity 
cannot be ignored. This is not a surprise, but it is surprising how 
little consideration there has been on how space and time in-
teract in elimination dynamics. Fronterre et al [17] demonstrate 
the impact of spatial heterogeneity on the design and analysis 
of surveys aimed at assessing elimination, with a focus on lym-
phatic filariasis. They demonstrate the enormous improvement 
in statistical efficiency that can be obtained by taking proper ac-
count of spatial correlations (ie, that places nearer to each other 
are more similar) when estimating prevalence. Whilst these ex-
pected gains in efficiency are disease and country specific, the 
general methodology can be applied to all infectious diseases.
WHERE WE ARE GOING...
With elimination as the end goal for NTD programs, it is 
not feasible to sample everyone everywhere once programs 
are halted, so practical surveillance schemes are needed. 
Such surveillance is of great importance to ensure that the 
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Figure 2. Model predictions for visceral leishmaniasis (VL) showing the impact of improved detection vs prior to improved detection where 50% of cases died before de-
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hard-won gains are maintained. In this special collection, we 
use modelling insights to provide highly valuable guidance 
on the surveillance that is required. To improve and validate 
the guidance, models are demanding more data. Additionally, 
better diagnostics will improve the quality of the data and 
the decisions made. Looking ahead to a hopeful future with 
well-designed surveillance schemes, the certainty with which 
decision makers can certify elimination will beneficially im-
prove, allowing us to rightfully celebrate reaching this end 
goal for NTDs.
The papers in this collection were written during 2019, be-
fore coronavirus 2019 (COVID-19) emerged as a pandemic. 
This will likely be the biggest global public health and eco-
nomic crisis for decades. Its impact on NTD elimination is still 
to be determined. On one hand the cessation of interventions 
is likely to see local resurgence for some diseases, but longer-
term public health and the necessity for surveillance may have a 
higher profile. Understanding the situation after the pandemic 
has subsided will be a major undertaking—well-designed, 
cost-effective surveillance is always critically important.
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